TimesSquare Capital Management LLC purchased a new position in Charles River Laboratories International, Inc. (NYSE:CRL) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 325,700 shares of the medical research company’s stock, valued at approximately $35,182,000. TimesSquare Capital Management LLC owned approximately 0.68% of Charles River Laboratories International at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Bridgewater Associates LP bought a new position in Charles River Laboratories International during the second quarter valued at approximately $679,000. Prudential Financial Inc. raised its position in Charles River Laboratories International by 19.0% during the second quarter. Prudential Financial Inc. now owns 425,860 shares of the medical research company’s stock valued at $43,076,000 after acquiring an additional 68,058 shares in the last quarter. American Century Companies Inc. bought a new position in Charles River Laboratories International during the second quarter valued at approximately $292,000. Northern Trust Corp raised its position in Charles River Laboratories International by 1.5% during the second quarter. Northern Trust Corp now owns 436,860 shares of the medical research company’s stock valued at $44,188,000 after acquiring an additional 6,304 shares in the last quarter. Finally, Shaker Investments LLC OH raised its position in Charles River Laboratories International by 25.6% during the third quarter. Shaker Investments LLC OH now owns 8,040 shares of the medical research company’s stock valued at $868,000 after acquiring an additional 1,640 shares in the last quarter. 98.72% of the stock is owned by institutional investors and hedge funds.

Several equities analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. BidaskClub lowered shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Robert W. Baird set a $117.00 price objective on shares of Charles River Laboratories International and gave the company a “buy” rating in a research report on Monday, November 13th. Bank of America Corporation cut their price objective on shares of Charles River Laboratories International from $117.00 to $115.00 and set a “buy” rating on the stock in a research report on Friday, November 10th. Finally, Jefferies Group LLC raised their price objective on shares of Charles River Laboratories International from $120.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, October 9th. Seven research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $106.63.

Charles River Laboratories International, Inc. (NYSE CRL) opened at $101.80 on Friday. Charles River Laboratories International, Inc. has a twelve month low of $69.51 and a twelve month high of $119.05. The company has a current ratio of 1.88, a quick ratio of 1.62 and a debt-to-equity ratio of 1.13. The company has a market capitalization of $4,821.45, a P/E ratio of 20.00, a price-to-earnings-growth ratio of 1.62 and a beta of 0.94.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Thursday, November 9th. The medical research company reported $1.30 EPS for the quarter, beating the consensus estimate of $1.22 by $0.08. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. The company had revenue of $464.23 million for the quarter, compared to the consensus estimate of $458.93 million. During the same quarter last year, the company posted $1.18 earnings per share. The company’s revenue for the quarter was up 9.0% compared to the same quarter last year. equities research analysts forecast that Charles River Laboratories International, Inc. will post 5.13 EPS for the current year.

In other Charles River Laboratories International news, insider Bradley Nixon Scharfe sold 1,000,000 shares of the stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $0.27, for a total transaction of $270,000.00. Also, insider Davide Molho sold 5,982 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $107.55, for a total value of $643,364.10. Following the transaction, the insider now owns 22,714 shares in the company, valued at approximately $2,442,890.70. The disclosure for this sale can be found here. In the last quarter, insiders have acquired 10,500 shares of company stock worth $2,885 and have sold 1,012,147 shares worth $1,591,514. Company insiders own 2.20% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “TimesSquare Capital Management LLC Takes Position in Charles River Laboratories International, Inc. (CRL)” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.watchlistnews.com/timessquare-capital-management-llc-takes-position-in-charles-river-laboratories-international-inc-crl/1727197.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.